Erisyon is a company headquartered in the United States. Brouky records 1 investor associated with the company.
Erisyon develops the world's first single-molecule protein sequencer using a technology called Fluorosequencing to enable highly sensitive, massively parallel, and quantitative proteomics for earlier disease detection and treatment.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.